News
-
Jeffrey Glenn granted $14.3 million to develop broad spectrum drugs
Researchers are pursuing antiviral drugs with broad efficacy against enteroviruses, which cause common colds and polio, and coronaviruses including the one that causes COVID
October 05, 2020
-
The Innovative Medicines Accelerator turns its focus on COVID-19
Stanford’s new IMA arose before the COVID-19 pandemic struck, but now its programs are focused entirely on helping faculty generate and test new medicines to slow the spread.
May 21, 2020
-
ChEM-H researchers work toward new understanding of cancer camouflage
A group led by ChEM-H Institute Scholar Lingyin Li and Chemistry/Biology Interface graduate student Jacqueline Carozza found a molecule that could help undermine cancer's defenses.
February 24, 2020
-
Antiviral treatments lead researchers to develop possible cancer drug
An effort to thwart viral diseases like hepatitis or the common cold led to a new collaboration and a novel class of cancer drugs that appears effective in mice.
January 23, 2020
-
Zinc chelation may be able to deliver drug to insulin-producing cells
By delivering a drug directly to beta cells, researchers may be able to spur insulin production and potentially develop a diabetes therapy in the future.
December 11, 2018
-
Researchers use zinc to target insulin-producing cells with regenerative drug
To treat diabetes directly, doctors need a way to get drugs to cells that produce insulin. The key, Stanford researchers report, may be those cells’ affinity for zinc.
December 06, 2018
-
Stars of Stanford Medicine: “I want to leave an impact on medical care”
Physician-scientist Justin Annes specializes in a rare type of tumor disorders. He shares his story, and interests, in this Stars of Stanford Medicine Q&A.
September 28, 2017
-
$28 million grant launches Center of Excellence for Translation Research
Jeffrey Glenn, MD, PhD, is leading a new center to develop antiviral therapies that target the host cell instead of the virus.
June 09, 2014